Fate Therapeutics Inc Stock as Institutional Investors Enter

September 16, 2018 - By Yee Bell

Sentiment for Fate Therapeutics Inc (NASDAQ:FATE)

Fate Therapeutics Inc (NASDAQ:FATE) institutional sentiment increased to 2.14 in Q2 2018. Its up 0.06, from 2.08 in 2018Q1. The ratio has increased, as 62 funds opened new and increased stock positions, while 29 sold and reduced their holdings in Fate Therapeutics Inc. The funds in our partner’s database now have: 39.35 million shares, up from 36.46 million shares in 2018Q1. Also, the number of funds holding Fate Therapeutics Inc in their top 10 stock positions decreased from 2 to 1 for a decrease of 1. Sold All: 12 Reduced: 17 Increased: 34 New Position: 28.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company has market cap of $621.27 million. The Company’s immuno-oncology product candidates include FATE-NK100, a natural killer cell cancer immunotherapy that consists of adaptive memory NK cells; engineered hnCD16 induced pluripotent stem cells (iPSC)-derived natural killer cell therapy candidates for hematologic/solid tumors; and engineered chimeric antigen receptor iPSC-derived T cell therapy product candidates for hematologic/solid tumors. It currently has negative earnings. The companyÂ’s immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and ToleraCyte for the treatment of autoimmune and inflammatory diseases; engineered iPSC-derived CD34+ cell therapy for immune disorders.

The stock decreased 1.11% or $0.13 during the last trading session, reaching $11.63. About 357,429 shares traded. Fate Therapeutics, Inc. (NASDAQ:FATE) has risen 181.90% since September 16, 2017 and is uptrending. It has outperformed by 166.28% the S&P500.

Analysts await Fate Therapeutics, Inc. (NASDAQ:FATE) to report earnings on November, 7. They expect $-0.27 earnings per share, down 3.85 % or $0.01 from last year’s $-0.26 per share. After $-0.37 actual earnings per share reported by Fate Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -27.03 % EPS growth.

Polaris Venture Management Co. V L.L.C. holds 15.28% of its portfolio in Fate Therapeutics, Inc. for 2.47 million shares. Redmile Group Llc owns 6.66 million shares or 2.56% of their US portfolio. Moreover, 683 Capital Management Llc has 0.57% invested in the company for 744,011 shares. The Luxembourg-based Artal Group S.A. has invested 0.41% in the stock. Endurant Capital Management Lp, a California-based fund reported 82,572 shares.

Fate Therapeutics, Inc. (NASDAQ:FATE) Ratings Coverage

Ratings analysis reveals 75% of Fate Therapeutics’s analysts are positive. Out of 4 Wall Street analysts rating Fate Therapeutics, 3 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $1200 while the high is $2000. The stock’s average target of $17.50 is 50.47% above today’s ($11.63) share price. FATE was included in 5 notes of analysts from March 20, 2018. H.C. Wainwright maintained Fate Therapeutics, Inc. (NASDAQ:FATE) on Thursday, March 29 with “Hold” rating. Piper Jaffray maintained it with “Buy” rating and $2000 target in Wednesday, May 16 report. Wells Fargo maintained Fate Therapeutics, Inc. (NASDAQ:FATE) on Friday, April 6 with “Buy” rating. As per Tuesday, March 20, the company rating was maintained by H.C. Wainwright.

Another recent and important Fate Therapeutics, Inc. (NASDAQ:FATE) news was published by Nasdaq.com which published an article titled: “Fate Therapeutics Enters into Exclusive License Agreement with Gladstone Institutes for CRISPR-based Cellular …” on September 13, 2018.

Fate Therapeutics, Inc. (NASDAQ:FATE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.